查詢結果分析
相關文獻
- Definitive Radiotherapy with Or Without Chemotherapy for Resectable Head and Neck Cancer
- Post-Operative Combination of Radiotherapy and Chemotherapy in Esophageal Cancer
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- Primary Radiotherapy Treatment Results of Maxillary Sinus Squamous Cell Carcinoma
- 晚期鼻咽癌同步化學放射治療與單獨放射治療臨床結果之比較--隨機分組試驗初步報告
- Peripheral Primitive Neuroectodermal Tumor: Report of a Case
- Radiotherapy Versus Combined Radiotherapy and Chemotherapy for T[feb2]Nasopharyngeal Carcinoma
- A Phase Ⅱ Trial of Concurrent Chemoradiation with Weekly Cisplatin and Glutathione for Bulky Advanced Cervical Cancer
頁籤選單縮合
題 名 | Definitive Radiotherapy with Or Without Chemotherapy for Resectable Head and Neck Cancer=使用放射治療或合併化學治療之方式治療可切除之頭頸部腫瘤 |
---|---|
作 者 | 成佳憲; 鄭鴻鈞; 簡哲民; 閻愷正; 詹光裕; 謝政毅; | 書刊名 | 放射治療與腫瘤學 |
卷 期 | 6:1 1999.03[民88.03] |
頁 次 | 頁33-39 |
分類號 | 416.36 |
關鍵詞 | 可切除之頭頸部腫瘤; 放射治療; 化學治療; 合併治療; Resectable head and neck cancers; Radiotherapy; Chemotherapy; Concurrent; |
語 文 | 英文(English) |
中文摘要 | 目的:回顧性分析以放射治療或合併化學治療之方式治療可切除之頭頸部腫瘤的 可行性、治療副作用及存活率。材料與方法:三十位診斷為可切除之頭頸部腫瘤病人接受根 治性放射治療或合併化學治療。一位病人為第一期,四位第二期,三位第三期,二十二位第 四期疾病。 放射治療為一日一次或一日兩次,總劑量為 68-74Gy。 化學治療使用 CDDP 與 5-FU, 包括兩次放射治療中的合併治療, 與兩次放射治療後的治療。 以 Kaplan-Meier method 分析存活率,以 long-rank test 分析預後因子。結果:追蹤時間之中位數為 50.8 個月。 四年整體整活率、無病存活率及局部控制率分別為 55.7 %、64.9 %及 75.8 %。 治療相關的副作屬可忍受。 T1/T2 腫瘤的病人在統計上具有意義的較佳局部控制率( p=0.03 )。 治療結束後的核磁共振或電腦斷層檢查中若有殘存疾病的病人,具統計上有意 義的較差整體存活率( p=0.05 )、 無病存活率( p=0.009 )及局部無再發存活率( p=0.001 )。 結論:放射治療或合併化學治療之方式治療可切除之頭頸部腫瘤可考慮為根 除手術外的一種選擇。它具有可接受的治療相關副作用及存活率。治療結束後的核磁共振或 電腦斷層檢查中若有殘存疾病的病人,應接受進一步探查與治療。 |
英文摘要 | Purpose:To retrospectively analyze the feasibility, toxicity and outcome of definitive radiotherapy with or without chemotherapy for patients with resectable head and neck cancers. Materials and Methods: Thirty patients with resectable head and neck cancers were treated with definitive split-course radiotherapy with or without concurrent chemotherapy. One patient had stagel, 4 Ⅰ stage, Ⅱ 3 stage Ⅲ and 22 stage Ⅳ diseases. Radiotherapy was given once daily or twice daily with total dose of 68-74 Gy. Chemotherapy included 2 cycles with CDDP+/-5FU during radiotherapy, and 2 cycles with CDDP+5FU after radiation treatment. Survival outcome was calculated by the Kaplan-Meier method. Prognostic factors were determined by log-rank test. Results: The medial follow-up time was 50.8 months. The 4-year overall survival, disease-free survival and locoregional control rates were 55.7 %,64.9 % and 75.8 %, respectively. Treatment-related toxicities were tolerable. T1/T2 diseases were associated with better locoregional control ( p=0.03 ). The presence of residual disease on post-treatment MRI or CT was the prognostic factor for overall survival ( p=0.05 ), disease-free survival ( p=0.009 ) and locoregional recurrence-free survival ( p=0.0001 ). Conclusion: Definitive radiotherapy with or without chemotherapy can be an alternative to radical surgery for patients with resectable head and neck cancers, with acceptable toxicity and outcome. The presence of residual disease on post-treatment imaging studies demands further investigation and possibly salvage treatment. |
本系統中英文摘要資訊取自各篇刊載內容。